Clinical trials: EGFR-TKI-resistant Non-Small Cell Lung Cancer
EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
This study is a Phase I, single-arm, single-center, dose-escalation clinical trial designed to investigate the safety and efficacy of intrathecal injection of sacituzumab tirumotecan (sac-TMT) in patients with EGFR…
- Trial name
- NCT07702305
- Testing
- Sacituzumab tirumotecan
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
NSCLC
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
- Trial name
- NCT05078931
- Testing
- Pembrolizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer
TAURAS - T790 AURA ScreenFailure SOC Registry Study
The aim of this study is to evaluate clinical outcomes of 2nd line therapy in NSCLC patients without the T790M mutation, both independently and when compared indirectly with NSCLC patients with the T790M mutation in the T STAR…
- Trial name
- TAURAS (NCT02405247)
- Testing
- Patient Reported Outcome (PRO)
- Where
- 5 sites in United States, South Korea
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
The goal of this Phase 1 clinical trial is to learn whether all-trans retinoic acid (ATRA) combined with tislelizumab is safe and tolerable in adults with EGFR-mutant non-small cell lung cancer (NSCLC).
- Trial name
- A Phase 1 Clin (NCT07842887)
- Testing
- All-trans retinoic acid, Tislelizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer
The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI）resistance.
- Trial name
- NCT03811054
- Testing
- Apatinib（250mg/d） combined with EGFR-TKI
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital
Non-small Cell Lung Cancer
Detection Cell Free DNA in Lung Cancer Patients
third generation of EGFR-TKIs is the newest target therapy for NSCLC. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.Next generation sequencing is current the most…
- Trial name
- NCT02738593
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
EGFR-TKI-resistant Non-Small Cell Lung Cancer
TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC
This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.
- Trial name
- NCT07498595
- Testing
- TILs infusion
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University General Hospital
Non Small Cell Lung Cancer
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations.
- Trial name
- NCT03123484
- Testing
- β-elemene, EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
- Volunteers
- 80 people
- Sponsor
- China Medical University, China
Lung Neoplasms, Lung Cancer, Nonsmall Cell
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact…
- Conditions
- Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
- Trial name
- NCT03059641
- Where
- 14 sites in China
- Volunteers
- 300 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Non-small Cell Lung Cancer
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced…
- Trial name
- NCT06277674
- Testing
- Cadonilimab plus Pemetrexed and Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Nonsmall Cell Lung Cancer
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations.
- Trial name
- NCT03050411
- Testing
- Apatinib Mesylate Tablets, EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Third Hospital
Neoplasms, Neoplasm Metastasis
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Trial name
- NCT03797391
- Testing
- EMB-01
- Where
- 5 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Non-Small Cell Lung Cancer
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and…
- Trial name
- NCT02468661
- Testing
- INC280 single agent, erlotinib
- Where
- 32 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of EDB-102 Injection in patients with advanced non-small cell lung cancer (NSCLC) who have liver metastases.
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases, EGFR Gene Mutation
- Trial name
- NCT07461727
- Testing
- EDB-102
- Volunteers
- 15 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NSCLC, EGFR Activating Mutation
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET/CT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed…
- Conditions
- NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2
- Trial name
- NCT07685197
- Testing
- receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
Nonsmall Cell Lung Cancer
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC
- Trial name
- PRECENT (NCT02988141)
- Volunteers
- 100 people
- Sponsor
- Jianxing He
Bronchial Neoplasms
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib…
- Trial name
- EATON (NCT03516214)
- Testing
- EGF816, Trametinib
- Where
- 7 sites in Germany, Spain
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Conditions
- Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
- Trial name
- NCT03532698
- Testing
- Aspirin, Osimertinib
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-small Cell Lung Cancer, EGFR Gene Mutation
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
- Trial name
- NCT06071013
- Testing
- Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- China Medical University Hospital
Non-Small Cell Lung Cancer
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple…
- Trial name
- ORCHARD (NCT03944772)
- Testing
- Osimertinib, Savolitinib, Gefitinib
- Where
- 47 sites in United States, Denmark and 7 more
- Volunteers
- 247 people
- Sponsor
- AstraZeneca